Alibaba to Pay 600 Million Dollars to Settle US Claims Over Illegal Drug Sales

Alibaba and an affiliated U.S. payments company have agreed to pay $600 million to resolve a Justice Department investigation into illegal pharmaceutical and controlled-substance sales facilitated on the Chinese group's platforms — one of the largest such penalties against a Chinese tech company. Alibaba accepted responsibility for the conduct but did not admit criminal wrongdoing.

Naomi Fields July 2, 2026 at 9:18 AM

Alibaba, the Chinese e-commerce giant, has agreed to pay $600 million to settle a U.S. investigation into the sale of illegal drugs and controlled substances through its online marketplaces — a rare, large penalty against a major Chinese company and a signal of Washington's growing scrutiny of the platforms that move goods into the United States.

The settlement

The agreement, announced by the Justice Department, resolves allegations against Alibaba and an affiliated U.S. payments company over sales that regulators say the platforms failed to stop, Al Jazeera reported. According to the department, the $600 million is split between criminal penalties and forfeitures across the two entities, the Justice Department said. The companies entered non-prosecution agreements — accepting responsibility for the conduct described by prosecutors without pleading guilty to a crime — and agreed to a period of independent compliance monitoring.

What prosecutors alleged

The government said that, over a span of years, the platforms facilitated tens of thousands of sales of illegal pharmaceuticals, controlled substances and related items — including equipment used to make pills — with a combined value in the hundreds of millions of dollars, as The Washington Post reported. Investigators said the companies' safeguards, including checks meant to screen out illicit sellers, fell short, allowing merchants to reach U.S. customers.

Alibaba's response

Alibaba framed the resolution as the end of a regulatory process it had cooperated with. The settlement "reflects a thorough regulatory process with Alibaba's full cooperation and our commitment to best-in-class standards of control, policies, and measures against non-compliant product sales," the company said in a statement quoted by Al Jazeera.

The bigger picture

The case lands amid heightened U.S. concern over how e-commerce platforms police what moves across them — especially drugs and the chemical precursors used to make fentanyl — and amid broader tension between Washington and Beijing over trade and technology. For Alibaba, the payment closes a legal cloud; for U.S. regulators, it is a marker that they intend to hold global marketplaces accountable for what is sold on them.